- Home
- DTSQ vs ARMP Comparison
DTSQ vs ARMP Comparison
Compare DTSQ & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- ARMP
- Stock Information
- Founded
- DTSQ 2022
- ARMP N/A
- Country
- DTSQ United States
- ARMP United States
- Employees
- DTSQ N/A
- ARMP N/A
- Industry
- DTSQ
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTSQ
- ARMP Health Care
- Exchange
- DTSQ NYSE
- ARMP Nasdaq
- Market Cap
- DTSQ 89.0M
- ARMP 80.0M
- IPO Year
- DTSQ 2024
- ARMP N/A
- Fundamental
- Price
- DTSQ $10.03
- ARMP $2.72
- Analyst Decision
- DTSQ
- ARMP Strong Buy
- Analyst Count
- DTSQ 0
- ARMP 1
- Target Price
- DTSQ N/A
- ARMP $7.00
- AVG Volume (30 Days)
- DTSQ 5.5K
- ARMP 8.3K
- Earning Date
- DTSQ 01-01-0001
- ARMP 11-13-2024
- Dividend Yield
- DTSQ N/A
- ARMP N/A
- EPS Growth
- DTSQ N/A
- ARMP N/A
- EPS
- DTSQ 0.24
- ARMP N/A
- Revenue
- DTSQ N/A
- ARMP $3,719,000.00
- Revenue This Year
- DTSQ N/A
- ARMP N/A
- Revenue Next Year
- DTSQ N/A
- ARMP $83.33
- P/E Ratio
- DTSQ $42.61
- ARMP N/A
- Revenue Growth
- DTSQ N/A
- ARMP N/A
- 52 Week Low
- DTSQ $9.96
- ARMP $1.93
- 52 Week High
- DTSQ $10.06
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- ARMP 67.03
- Support Level
- DTSQ N/A
- ARMP $2.21
- Resistance Level
- DTSQ N/A
- ARMP $2.96
- Average True Range (ATR)
- DTSQ 0.00
- ARMP 0.15
- MACD
- DTSQ 0.00
- ARMP 0.05
- Stochastic Oscillator
- DTSQ 0.00
- ARMP 68.42
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.